Darren Hauck/Getty Images
Associate research specialist at the Wisconsin National Primate Research Center at University Wisconsin-Madison removes a new batch of Embryonic Stem Cells from deep freeze to be thawed before being worked on.
My KPCC colleague Stephanie O'Neill contributed a must-listen report to a recent broadcast of "The Madeleine Brand Show." It was all about the economics of stem-cell research and how this kind of very high-tech, advanced medical therapy is imperative for the future of the country's population. Here's a sample:
Right now the US spends about $2.7 trillion health care annually, a figure that's expected to soar with an aging and increasingly obese population.
"Traditional approaches, whether it's through the use of pharmaceuticals or traditional types of biologics or devices or surgical intervention, really are not going to be able to effectively deal with the challenges we face," said Gil Van Bokkelen, chairman of the non-profit Alliance for Regenerative Medicine in Washington DC and CEO of the Ohio-based biotech firm, Athersys.
"What I think is going to happen over the course of the next several years is we're going to see the first clinical evidence that shows how big of an impact these types of therapies can really have. Which means we can overcome some of the rising tide of pressure that we're trying to fight against with an aging population that's more susceptible to a lot of different, very expensive disease conditions."